NO327609B1 - Svekkede muterte bakterier anvendelige i vaksiner. - Google Patents

Svekkede muterte bakterier anvendelige i vaksiner. Download PDF

Info

Publication number
NO327609B1
NO327609B1 NO20004781A NO20004781A NO327609B1 NO 327609 B1 NO327609 B1 NO 327609B1 NO 20004781 A NO20004781 A NO 20004781A NO 20004781 A NO20004781 A NO 20004781A NO 327609 B1 NO327609 B1 NO 327609B1
Authority
NO
Norway
Prior art keywords
gene
bacteria
salmonella
mutation
vaccine
Prior art date
Application number
NO20004781A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004781D0 (no
NO20004781L (no
Inventor
Steven Neville Chatfield
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20004781D0 publication Critical patent/NO20004781D0/no
Publication of NO20004781L publication Critical patent/NO20004781L/no
Publication of NO327609B1 publication Critical patent/NO327609B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
NO20004781A 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner. NO327609B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (fr) 1998-03-25 1999-03-25 Bacteries attenuees par mutation irreversible de chacun des genes aroc, ompf et ompc, utiles dans des vaccins

Publications (3)

Publication Number Publication Date
NO20004781D0 NO20004781D0 (no) 2000-09-25
NO20004781L NO20004781L (no) 2000-11-08
NO327609B1 true NO327609B1 (no) 2009-08-31

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004781A NO327609B1 (no) 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner.

Country Status (19)

Country Link
US (1) US6902906B1 (fr)
EP (1) EP1066376B1 (fr)
JP (1) JP4516210B2 (fr)
KR (1) KR100628657B1 (fr)
AT (1) ATE296881T1 (fr)
AU (1) AU763683B2 (fr)
CA (1) CA2323576C (fr)
CZ (1) CZ301520B6 (fr)
DE (1) DE69925585T2 (fr)
DK (1) DK1066376T3 (fr)
ES (1) ES2244182T3 (fr)
GB (1) GB9806449D0 (fr)
HU (1) HU225644B1 (fr)
NO (1) NO327609B1 (fr)
NZ (1) NZ507077A (fr)
PL (1) PL196076B1 (fr)
PT (1) PT1066376E (fr)
WO (1) WO1999049026A1 (fr)
ZA (1) ZA200004987B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
EP1352245B1 (fr) * 2001-01-18 2006-08-16 Newcastle University Ventures Limited Biocapteur a proteines transmembranaires attachees de maniere covalente
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
EP1981536A4 (fr) * 2006-02-01 2012-03-14 Gotovax Ab Antigenes de facteur de colonisation d'escherichia coli enterotoxigenes dans des bacteries recombinees
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
JP2011502165A (ja) * 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
WO2014037445A1 (fr) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Préparation de vaccins vivants
PL3415643T3 (pl) * 2012-09-05 2020-06-01 Lohmann Animal Health Gmbh Wytwarzanie żywych szczepionek
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (fr) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions et procedes pour ameliorer les reactions immunitaires aux pathogenes enteriques
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) * 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
DK0574466T3 (da) * 1991-03-05 1999-11-08 Wellcome Found Udtrykkelse af rekombinante proteiner i svækkede bakterier

Also Published As

Publication number Publication date
KR100628657B1 (ko) 2006-09-26
AU763683B2 (en) 2003-07-31
AU3045899A (en) 1999-10-18
CZ20003470A3 (cs) 2001-07-11
HUP0105430A2 (hu) 2002-04-29
CA2323576C (fr) 2010-12-07
ZA200004987B (en) 2001-10-31
HUP0105430A3 (en) 2004-10-28
KR20010042175A (ko) 2001-05-25
HU225644B1 (en) 2007-05-02
DE69925585D1 (de) 2005-07-07
CA2323576A1 (fr) 1999-09-30
ES2244182T3 (es) 2005-12-01
JP4516210B2 (ja) 2010-08-04
US6902906B1 (en) 2005-06-07
GB9806449D0 (en) 1998-05-27
EP1066376A1 (fr) 2001-01-10
DE69925585T2 (de) 2006-07-13
PL196076B1 (pl) 2007-12-31
NO20004781D0 (no) 2000-09-25
EP1066376B1 (fr) 2005-06-01
NO20004781L (no) 2000-11-08
ATE296881T1 (de) 2005-06-15
CZ301520B6 (cs) 2010-03-31
JP2002507414A (ja) 2002-03-12
NZ507077A (en) 2002-10-25
PT1066376E (pt) 2005-10-31
WO1999049026A1 (fr) 1999-09-30
DK1066376T3 (da) 2005-10-03
PL343246A1 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
US6399074B1 (en) Live attenuated salmonella vaccines to control avian pathogens
NO327609B1 (no) Svekkede muterte bakterier anvendelige i vaksiner.
CA2244807A1 (fr) Vaccin produit a partir de salmonella typhimurium
Ahmed et al. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y
DK2879700T3 (en) Hitherto unknown live attenuated Shigella vaccine
Dilts et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity
Su et al. Regulated delayed Shigella flexneri 2a O-antigen synthesis in live recombinant Salmonella enterica serovar Typhimurium induces comparable levels of protective immune responses with constitutive antigen synthesis system
Newland et al. Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen
Mills et al. Analysis and genetic manipulation of Shigella virulence determinants for vaccine development
US20230372462A1 (en) High dose shigella vaccine preparation
US6905691B1 (en) Vaccines containing attenuated bacteria
Zhao et al. Regulated delayed attenuation enhances the immunogenicity and protection provided by recombinant Salmonella enterica serovar Typhimurium vaccines expressing serovar Choleraesuis O-polysaccharides
WO1999029342A1 (fr) Vaccins contenant des bacteries attenuees
CN101730737A (zh) 超表达重组霍乱毒素b亚单位的霍乱弧菌显示双重免疫原性
MXPA00009354A (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees